Skip to main content

Table 3 Serious adverse events

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Patient PIN Event Duration of experimental therapy Attribution
178 Pneumothorax due to central line insertion. Death 5 days Not related
384 Malignancy. Death 139 days Probably not related
663 Sudden death 11 days Not related
459 Severe pneumonia with respiratory failure 6 months (17 days after the last dose of imatinib) Unlikely related